[HTML][HTML] Applications and analysis of targeted genomic sequencing in cancer studies
Abstract Next Generation Sequencing (NGS) has dramatically improved the flexibility and
outcomes of cancer research and clinical trials, providing highly sensitive and accurate high …
outcomes of cancer research and clinical trials, providing highly sensitive and accurate high …
[HTML][HTML] Proteasomes and several aspects of their heterogeneity relevant to cancer
AV Morozov, VL Karpov - Frontiers in Oncology, 2019 - frontiersin.org
The life of every organism is dependent on the fine-tuned mechanisms of protein synthesis
and breakdown. The degradation of most intracellular proteins is performed by the ubiquitin …
and breakdown. The degradation of most intracellular proteins is performed by the ubiquitin …
[HTML][HTML] Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence
K Misund, D Hofste Op Bruinink, E Coward… - Leukemia, 2022 - nature.com
We investigated genomic and transcriptomic changes in paired tumor samples of 29 in-
house multiple myeloma (MM) patients and 28 patients from the MMRF CoMMpass study …
house multiple myeloma (MM) patients and 28 patients from the MMRF CoMMpass study …
[HTML][HTML] Proteasome inhibition in multiple myeloma: head-to-head comparison of currently available proteasome inhibitors
A Besse, L Besse, M Kraus, M Mendez-Lopez… - Cell chemical …, 2019 - cell.com
Proteasome inhibitors (PIs) are a backbone of multiple myeloma (MM) therapy. The
proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified …
proteasome harbors six proteolytically active subunits (β1, β2, β5), while β5 was identified …
The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges
GR Tundo, D Sbardella, AM Santoro, A Coletta… - Pharmacology & …, 2020 - Elsevier
Abstract Ubiquitin Proteasome System (UPS) is an adaptable and finely tuned system that
sustains proteostasis network under a large variety of physiopathological conditions. Its …
sustains proteostasis network under a large variety of physiopathological conditions. Its …
Understanding drug sensitivity and tackling resistance in cancer
Decades of research into the molecular mechanisms of cancer and the development of
novel therapeutics have yielded a number of remarkable successes. However, our ability to …
novel therapeutics have yielded a number of remarkable successes. However, our ability to …
Chemical strategies to overcome resistance against targeted anticancer therapeutics
Emergence of resistance is a major factor limiting the efficacy of molecularly targeted
anticancer drugs. Understanding the specific mutations, or other genetic or cellular changes …
anticancer drugs. Understanding the specific mutations, or other genetic or cellular changes …
[HTML][HTML] Genome instability in multiple myeloma: Facts and factors
Simple Summary Multiple myeloma is an incurable blood cancer caused by the malignant
transformation of immunoglobulin-producing plasma cells. The mechanisms leading to the …
transformation of immunoglobulin-producing plasma cells. The mechanisms leading to the …
[HTML][HTML] Non-hematologic toxicity of bortezomib in multiple myeloma: The neuromuscular and cardiovascular adverse effects
E Pancheri, V Guglielmi, GM Wilczynski, M Malatesta… - Cancers, 2020 - mdpi.com
Simple Summary Multiple myeloma (MM) is a still uncurable tumor of mainly elderly patients
originating from the terminally differentiated B cells. Introduction to the treatment of MM …
originating from the terminally differentiated B cells. Introduction to the treatment of MM …
[HTML][HTML] Overcoming proteasome inhibitor resistance in the immunotherapy era
Proteasome inhibitors (PIs) are a fascinating class of small molecules that disrupt protein
homeostasis and are highly efficacious in the blood cancer multiple myeloma. However, PIs …
homeostasis and are highly efficacious in the blood cancer multiple myeloma. However, PIs …